Novartis announced one of its top legal experts, who signed a $1.2m contract with Michael Cohen in February 2017, is resigningSwiss pharmaceutical giant Novartis on Wednesday announced the retirement of its top legal expert, as he apologised for payments made by the firm to Donald Trump’s personal lawyer Michael Cohen.The announcement came after Novartis was dragged into the scandal over Cohen’s payment of $130,000 to US adult film actor Stormy Daniels just days before the 2016 presidential election. Continue reading...
Cohen has said he provided consultancy services rather than lobbying, and is not required by law to register as a lobbyist and disclose paymentsThe disclosure that Donald Trump’s legal fixer Michael Cohen was quietly paid hundreds of thousands of dollars to advise corporations highlights the inability of US laws to prevent secretive “shadow lobbying”, analysts said.Companies such as the telecoms giant AT&T and Novartis, a major pharmaceuticals firm, confirmed they paid Cohen, the president’s personal attorney, large sums last year in return for what they describe as guidance on navigating the new administration. Continue reading...
Deutsche Telekom boss cries ‘competition’ over Vodafone deal but is he on board for BT’s superfast broadband rollout?BT often gets stick for being an over-privileged incumbent that hates the whiff of real competition, so it’s almost comforting to know that its German equivalent, Deutsche Telekom, fits the caricature more precisely.Witness DT chief executive officer Tim Höttges’s wildly over-the-top reaction to the news that Vodafone is buying US group Liberty Global’s cable assets in the country in a €18.4bn (£16.1) deal that also involves operations in the Czech Republic, Hungary and Romania. “Totally unacceptable,” Höttges told Bloomberg, which described him as being “visibly worked up”. Continue reading...
Novartis confirms it paid Trump’s lawyer’s company $1.2m – significantly more than was initially disclosedRobert Mueller, the special counsel, has been investigating payments made by corporations to Donald Trump’s attorney Michael Cohen, two of Cohen’s clients said on Wednesday.AT&T and the Swiss pharmaceuticals company Novartis both said they were contacted by Mueller’s office in November last year, as Novartis confirmed it had paid Cohen $1.2m – significantly more than was initially disclosed. Continue reading...
Крупнейшие фармацевтические компании мира делают ставку на квантовые компьютеры, технологию обработки больших данных и искусственный интеллект. Например, корпорация Novartis разработала систему программного обеспечения Nerve, которая не только отслеживает весь поток данных по каждому из 550 клинических испытаний лекарств компании, но и использует аналитику больших данных, чтобы предсказать возможные сбои в проведении испытаний. Вся эта информация... Читать далее Сообщение Технологии помогут найти лекарства от всех болезней появились сначала на Компьютерра.
ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.
Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.
Takeda expressed its intention to take over Shire (SHPG) to boost its geographic presence and product portfolio.
Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.
Japan’s Takeda Pharmaceutical said it is considering the acquisition of Shire PLC whose market cap of $40 billion (before the announcement) makes it one of the world's largest pharma companies. Takeda said a deal with Shire would create a global biopharmaceutical leader, strengthening the Japanese company’s core therapeutic areas of oncology, gastrointestinal disorders, and neuroscience. The acquisition would leave Takeda with a portfolio of specialty drugs with a particular focus on gastrointestinal diseases and nervous system ailments, according to Bloomberg and WSJ. Takeda said it hasn’t approached Shire’s board yet and the proposal is at a “preliminary and exploratory” stage. The Japanese pharma didn’t disclose any financial details of a potential offer. Japan’s biggest drugmaker has signaled it’s ready to take on more deals and partnerships as it seeks to build an identity beyond its home market, where a shrinking population limits growth opportunities. With a market value of about $42 billion, Takeda is smaller than the potential takeover target after Shire’s rally Wednesday, which has pushed Shire's market cap to approximately $50 billion. Shire's shares soared more than 20% on the news before paring back some gains. Still, with today's move the stock price of Shire is only back to where it was at the beginning of the year. The Massachusetts-based, London-listed Shire previously tried and failed to complete an "inversion" deal with AbbVie after the Obama administration introduced new rules to discourage inversions. Takeda also said acquiring Shire would balance its geographic focus to align with the market opportunity in the US. The potential deal would unfold against a backdrop of other pharma mergers and buyouts - including GSK's $13 billion agreement to buy out its joint venture with Novartis. This is just the latest transaction for Takeda which made a slew of deals in 2018: it announced an offer to acquire TiGenix NV, a Belgian maker of stem-cell therapies, for 520 million euros ($645 million) in January, as well as a $150 million initial payment to Denali Therapeutics Inc. for a partnership to develop drugs for neurodegenerative diseases. In February, Takeda promised another $230 million to Wave Life Sciences for a pact on treatments for disorders of the central nervous system. According to Bloomberg, Takeda still has the scope for acquisitions after the $4.7 billion purchase of U.S. biotech Ariad Pharmaceuticals Inc. last year, Chief Executive Officer Christophe Weber said in a November interview. He said then that the company is mainly focused on forming more research partnerships and moving its pipeline products into later stages of development to help drive growth. Shire would give Takeda a broader portfolio in the U.S. as well as an entree to the hemophilia market, which fits Weber’s stated goal of expanding in more expensive drugs targeted to small patient groups. A deal for Shire would surpass Takeda’s 2011 acquisition of Nycomed for $13.7 billion including debt, according to data compiled by Bloomberg. Japanese companies have announced $26.5 billion of overseas acquisitions this year, up from $17.8 billion in the same period a year earlier.
Swiss group focuses on pharma as $13bn deal hands UK partner control of consumer unit
Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.
Novartis deal strengthens UK group’s bet on consumer health and clears up uncertainty
Швейцарская фармацевтическая компания Novartis заявила, что продаст 36,5%-ную долю в совместном бизнесе сферы здравоохранения своему партнеру GlaxoSmithKline, при этом сумма сделки составит $13 млрд наличными. Ожидается, что сделка, подлежащая одобрению регулятивных органов, будет завершена во втором квартале. Стоит отметить, что совместное предприятие сторон было создано в 2015 году, при этом в его продуктовый портфель входят такие известные препараты как Панадол, Вольтарен и Никотинелл.